A method of preparing 5,7-dihalo-1,4-dihydro-4-oxoquinoline-2-carboxylic acid tosylate addition salts is provided, which involves direct conversion of esters of Formula V as described herein to acids of Formula VIII as described herein. Tosylate addition salts of Formula IX as described herein are then prepared from the acids of Formula VIII.
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
3.
PROCESS FOR PREPARING 1,4-DIHYDRO-4-OXOQUINOLINE-2-CARBOXYLATES AND 4-AMINOQUINOLINE COMPOUNDS THEREFROM
4 alkyl. Optionally, a cosolvent such as dichloromethane can be included with the Eaton's reagent. A method of preparing a diphenylureido-dihalokynurenic acid alkyl ester of Formula VI from the compound of Formula IV also is described.
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I):
in which the substituents thereof are defined as set forth in the specification.
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Analgesic compositions comprise an aminoquinoline together with an opioid, a non steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.
Analgesic compositions comprise an aminoquinoline together with an opioid, a non-steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I):
in which the substituents thereof are defined as set forth in the specification.
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I):(see formula I)
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I):(see formula I)
Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.
The present invention relates to compositions and methods for identifying and quantifying platelet proteins that relate to various bodily states. The present invention further provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
The present invention relates to compositions and methods for determining whether an individual is predisposed to major depressive disorder and/or to bipolar disorder. In particular, the present invention provides genetic markers useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of major (unipolar) depression and/or bipolar disorder.
The present invention relates to compositions and methods for identifying and quantifying platelet proteins. As certain behaviors and medical conditions alter the quantity of various platelet membrane proteins, the tools of the present invention are suitable for identification of biomarkers of these bodily states. For instance, the present invention provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.
patents
